- Topline data from REVEAL anticipated in 2H 2027 - CARLSBAD, Calif. –(BUSINESS WIRE)–Jul. 6, 2026– Ionis Pharmaceuticals, Inc.
Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome
calendar_today
July 6, 2026
person
Ionis Pharmaceuticals, Inc. News Releases
domain
ionis-pharmaceuticals